PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
18854490-4	2009	TC-1, a potent inhibitor (IC(50) approximately 0.4 nM), has excellent passive membrane permeability, low susceptibility to P-glycoprotein transport, and lowered brain A beta levels in a mouse model.	TC 1	0-4	amyloid beta (A4) precursor protein	Mus musculus	167-173
18854490-5	2009	Intravenous infusion of TC-1 led to a significant but transient lowering of CSF and plasma A beta levels in conscious rhesus monkeys because it underwent CYP3A4-mediated metabolism.	TC 1	24-28	amyloid beta (A4) precursor protein	Mus musculus	91-97
18854490-5	2009	Intravenous infusion of TC-1 led to a significant but transient lowering of CSF and plasma A beta levels in conscious rhesus monkeys because it underwent CYP3A4-mediated metabolism.	TC 1	24-28	CYP3A4	Macaca mulatta	154-160
18854490-6	2009	Oral codosing of TC-1 with ritonavir, a potent CYP3A4 inhibitor, twice daily over 3.5 days in rhesus monkeys led to sustained plasma TC-1 exposure and a significant and sustained reduction in CSF sAPP beta, A beta 40, A beta 42, and plasma A beta 40 levels.	TC 1	17-21	CYP3A4	Macaca mulatta	47-53
18854490-6	2009	Oral codosing of TC-1 with ritonavir, a potent CYP3A4 inhibitor, twice daily over 3.5 days in rhesus monkeys led to sustained plasma TC-1 exposure and a significant and sustained reduction in CSF sAPP beta, A beta 40, A beta 42, and plasma A beta 40 levels.	TC 1	17-21	amyloid beta (A4) precursor protein	Mus musculus	207-213
18854490-6	2009	Oral codosing of TC-1 with ritonavir, a potent CYP3A4 inhibitor, twice daily over 3.5 days in rhesus monkeys led to sustained plasma TC-1 exposure and a significant and sustained reduction in CSF sAPP beta, A beta 40, A beta 42, and plasma A beta 40 levels.	TC 1	17-21	amyloid beta (A4) precursor protein	Mus musculus	218-224
18854490-6	2009	Oral codosing of TC-1 with ritonavir, a potent CYP3A4 inhibitor, twice daily over 3.5 days in rhesus monkeys led to sustained plasma TC-1 exposure and a significant and sustained reduction in CSF sAPP beta, A beta 40, A beta 42, and plasma A beta 40 levels.	TC 1	17-21	amyloid beta (A4) precursor protein	Mus musculus	218-224
18854490-7	2009	CSF A beta 42 lowering showed an EC(50) of approximately 20 nM with respect to the CSF [TC-1] levels, demonstrating excellent concordance with its potency in a cell-based assay.	TC 1	88-92	amyloid beta (A4) precursor protein	Mus musculus	4-10
19325708-6	2009	In pulmonary metastatic foci generated by TC-1 cells IV injection a high proportion of cells expressed membrane-associated CXCR4.	TC 1	42-46	C-X-C motif chemokine receptor 4	Homo sapiens	123-128
16844231-7	2006	More importantly, in both tumor prevention and tumor treatment assays, DC-Sig/E7/LAMP-1 generated greater anti-tumor immunity against TC-1 than DC-E7.	TC 1	134-138	lysosomal associated membrane protein 1	Homo sapiens	81-87
15214037-3	2004	A naked Sindbis RNA replicon vector (SINrep5) encoding the herpes simplex virus type 1 protein VP22 linked to E7 (SINrep5-VP22/E7) generated significant antitumor effects against TC-1 and TC-1 P3(A15), tumors with down-regulated MHC class I expression.	TC 1	179-183	naked	Mus musculus	2-7
15214037-4	2004	Naked SINrep5 RNA without the insert or an E7 vaccine also produced antitumor effects against TC-1 P3(A15) but not TC-1.	TC 1	94-98	naked	Mus musculus	0-5
1552290-5	1992	In the absence of IL-5, exceptionally high concentrations of IL-4 (greater than 1,000 U/ml) were required to elicit IgG1 and IgE secretion from B lymphoblasts cultured with either LPS or TC-1-conditioned media (CM).	TC 1	187-191	interleukin 4	Mus musculus	61-65
9164470-10	1997	Serum AFP levels were also elevated in the TC-1-bearing SCID mice.	TC 1	43-47	alpha fetoprotein	Mus musculus	6-9
11823127-10	2002	The highest ratio between areas reach and poor in 5-HT1A receptors was calculated for complex Tc-1 at 60 min p.i.	TC 1	94-98	5-hydroxytryptamine receptor 1A	Rattus norvegicus	50-56
8411809-0	1993	[Demonstration of interleukin-1 (IL-1) as an autocrine growth inhibitor in renal cancer cell line, TC-1].	TC 1	99-103	interleukin 1 beta	Homo sapiens	18-37
2936399-2	1985	The compound is an isomer of TC-1 (a recently isolated T-2 derivative) in which the hydroxy and acetoxy groups at the C-3 and C-4 positions, respectively, are reversed.	TC 1	29-33	complement C3	Bos taurus	118-121
2936399-2	1985	The compound is an isomer of TC-1 (a recently isolated T-2 derivative) in which the hydroxy and acetoxy groups at the C-3 and C-4 positions, respectively, are reversed.	TC 1	29-33	complement C4	Bos taurus	126-129
31654626-7	2019	The results show that the TRPM8 inhibitors BCTC, RQ-00203078, TC-1 2014, 2-APB, and clotrimazole blocked TRPM8-mediated activation of AP-1.	TC 1	62-66	transient receptor potential cation channel subfamily M member 8	Homo sapiens	26-31
33923750-5	2021	In vivo depletion experiments showed that the deactivation of CD80 switched the pro-tumorigenic effect of macrophages observed in TC-1-induced tumors into an anti-tumorigenic effect in TC-1/dCD80-1 tumors and induced the pro-tumorigenic activity of CD4+ cells.	TC 1	130-134	CD80 antigen	Mus musculus	62-66
33923750-6	2021	Moreover, the frequency of lymphoid and myeloid cells and the CTLA-4 expression by T helper (Th)17 cells were increased in TC-1/dCD80-1- compared with that in the TC-1-induced tumors.	TC 1	123-127	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	62-68
32479782-3	2020	Liposomal vaccine containing MPLA (TLR4 liposomes), are the most effective treatment against the HPV-transformed orthotopic lung tumor mouse model, TC-1.	TC 1	148-152	toll-like receptor 4	Mus musculus	35-39
31654626-7	2019	The results show that the TRPM8 inhibitors BCTC, RQ-00203078, TC-1 2014, 2-APB, and clotrimazole blocked TRPM8-mediated activation of AP-1.	TC 1	62-66	transient receptor potential cation channel subfamily M member 8	Homo sapiens	105-110
31654626-7	2019	The results show that the TRPM8 inhibitors BCTC, RQ-00203078, TC-1 2014, 2-APB, and clotrimazole blocked TRPM8-mediated activation of AP-1.	TC 1	62-66	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	134-138
30728820-7	2018	Altogether, our results demonstrate that intranasal administration with L. lactis secreting IL-17A results in a partial protection against TC-1-induced tumors in mice, confirming antitumor effects of this cytokine in our cancer model.	TC 1	139-143	interleukin 17A	Mus musculus	92-98
24066030-4	2013	The in vivo depletion of CD4(+) T cells one day before tumor challenge resulted in compromised vaccine efficacy in both TC-1 (25%) and 3LL (12.5%) tumor models.	TC 1	120-124	CD4 antigen	Mus musculus	25-28
29962199-0	2016	[Changes in the Expression of AKT and ERK after the JSRV-Env-Induced Transfection of TC-1 and TC-1-Hyal2 Cells].	TC 1	85-89	envelope protein	Jaagsiekte sheep retrovirus	57-60
19950168-2	2010	Here, we demonstrated that utilizing nonlytic Fc-fused IL-7 (IL-7-Fc(m)) as a genetic adjuvant significantly enhanced not only CD4(+) but also CD8(+) T-cell responses by E7 DNA immunization, in addition to improving protection against TC-1-induced tumors in comparison to IL-7 alone.	TC 1	235-239	interleukin 7	Homo sapiens	55-59
21182262-6	2011	On the other hand, the antagonistic function of Cby is inhibited upon binding to thyroid cancer-1 (TC-1).	TC 1	99-103	chibby family member 1, beta catenin antagonist	Homo sapiens	48-51
21182262-6	2011	On the other hand, the antagonistic function of Cby is inhibited upon binding to thyroid cancer-1 (TC-1).	TC 1	99-103	transcriptional and immune response regulator	Homo sapiens	81-97
21779410-9	2011	Anti-CTLA4 delivery as a protein or expression from gene-modified tumor cells were therapeutically efficacious in the non-tolerized TC-1 tumor model, but had no effect in the MMC-model.	TC 1	132-136	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	5-10
22926003-7	2013	Also in therapeutic experiment, our data showed that co-immunization of IP-10 at the same inoculation site of TC-1 along with E7-NT-gp96 delivery by PEI600-Tat is able to significantly suppress TC-1 tumor growth.	TC 1	110-114	chemokine (C-X-C motif) ligand 10	Mus musculus	72-77
19950168-2	2010	Here, we demonstrated that utilizing nonlytic Fc-fused IL-7 (IL-7-Fc(m)) as a genetic adjuvant significantly enhanced not only CD4(+) but also CD8(+) T-cell responses by E7 DNA immunization, in addition to improving protection against TC-1-induced tumors in comparison to IL-7 alone.	TC 1	235-239	interleukin 7	Homo sapiens	61-68
19950168-2	2010	Here, we demonstrated that utilizing nonlytic Fc-fused IL-7 (IL-7-Fc(m)) as a genetic adjuvant significantly enhanced not only CD4(+) but also CD8(+) T-cell responses by E7 DNA immunization, in addition to improving protection against TC-1-induced tumors in comparison to IL-7 alone.	TC 1	235-239	interleukin 7	Homo sapiens	61-65